Business
Avacta Therapeutics Presents Data from Lead pre|CISION® Candidate FAP-Dox (AVA6000) at the 2025 AACR Annual Meeting
Compelling Phase 1 safety and efficacy data for FAP-Dox (AVA6000) with preliminary evidence of efficacy in salivary gland cancers and no severe cardiac toxicity Progression free survival (PFS) data to date represents a near doubling of the benchmarking data in this patient population without reaching median PFS LONDON and PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting pow
About this update from Avacta Group Plc
[{"type":"image","alt":"AVACTA GROUP PLC","displaySize":"","headline":null,"caption":"AVACTA GROUP PLC","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":109,"url":"https://media.zenfs.com/en/globenewswire.com/2179b51c1f91cddf1addee3cc0dee04b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BuJbdPFE1KPW3OqbkUSHWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2179b51c1f91cddf1addee3cc0dee04b","width":300,"height":109}},"lazy":false},{"type":"text","content":"Compelling Phase 1 safety and efficacy data for FAP-Dox (AVA6000) with preliminary evidence of efficacy in salivary gland cancers and no severe cardiac toxicity","length":160,"tagName":"p"},{"type":"text","content":"Progression free survival (PFS) data to date represents a near doubling of the benchmarking data in this patient population without reaching median PFS","length":151,"tagName":"p"},{"type":"text","content":"LONDON and PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced Phase 1 data from its lead program FAP-Dox (AVA6000), that were presented alongside preclinical pharmacokinetic results from its second pre|CISION® candidate AVA6103 (FAP-EXd) at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL.","length":513,"tagName":"p"},{"type":"text","content":"Both programs are designed to target fibroblast activation protein-alpha (FAPα), the protease that forms the basis of the pre|CISION® platform. FAP is consistently overexpressed across a broad range of solid tumors and enriched at the tumor-stroma interface, making it an ideal target for tumor-localized drug activation. Avacta’s proprietary pre|CISION® chemistry leverages this tumor-specific biology to activate potent drugs selectively at the tumor site, enhancing efficacy while minimizing systemic toxicity.","length":513,"tagName":"p"},{"type":"text","content":""Today’s clinical results mark the achievement of a proof-of-concept milestone with our proprietary pre|CISION® platform demonstrating meaningful activity,” said Christina Coughlin, CEO of Avacta Therapeutics. “With AVA6000 demonstrating strong early signs of efficacy in a specif...